Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123248) titled 'A Multicenter Study to Assess the Efficacy and Safety of ropeginterferon alfa-2b in young adults with Essential Thrombocythemia (ET)' on April 23.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Condition:
Essential Thrombocythemia
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-05
Target Sample Size: Experimental Group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=319971
Disclaimer: Curated by HT Syndication....